Waters Says US FDA Clearance Obtained for Leukemia, Lymphoma Clinical Tests

10:08 AM EST, 11/10/2026 (MT Newswires) -- Waters' (WAT) BD OneFlow LST and BD OneFlow B-CLPD T1 tests have received 510(k) clearance from the US Food and Drug Administration, enabling commercialization in the US, the company said Tuesday. The tests aid in the identification and diagnosis of B-cell non-Hodgkin lymphoma, including chronic lymphocytic leukemia, the company said. The tests are available for preorder and will be commercially available in the US in spring 2027 through online ordering and local representatives, Waters said. Price: 470.16, Change: -6.57, Percent Change: -1.38